Clinical Data


Presentations, Posters & Abstracts

Back to top

Preclinical Data


Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism
Gracia-Sancho, J et al. Hepatol Comm 2019.
DOI: 10.1002/hep4.1360.

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis
Liao, L et al. Gut 2019;0:1–16.
DOI: 10.1136/gutjnl-2018-316670.

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation

Eguchi, A et al. J Mol Med (2018) 96:575-583.
DOI: 10.1007/s00109-018-1642-9.

Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Kopec A et al. Toxicol Sci. 162:2, 396-405. 1 April 2018.
DOI: 10.1093/toxsci/kfx268.

Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice
Guicciardi ME et al. Cell Death and Disease 2017.
DOI: 10.1038/cddis.2016.459.

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen
Xu M, et al. Nature Med. 2016 Aug 29 advance online publication.
DOI: 10.1038/nm.4184.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
Brumatti G, et al. Sci Transl Med. 2016 May 18;8(339):339ra69.
DOI: 10.1126/scitranslmed.aad3099.

Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice
Elbekai, RH et al. Regulatory Toxicology and Pharmacology 72 (2015) 169–178. 
DOI: 10.1016/j.yrtph.2015.04.007.

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
Barreyro FJ, et al. Liver Int. 2015 Mar; 35(3):953-66. 
DOI: 10.1111/liv.12570.

Caspase inhibitor IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant modelMcCall MD et al. Transplantation. 2012 Jul 15;94(1):30-5.
DOI: 10.1097/TP.0b013e318257745d.

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against a-Fas-induced liver injury in a mouse model
Ueno Y et al. J Pharmacol Sci. 2007 Oct;105(2):201-5.
DOI: 10.1254/jphs.SC0070207.

A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemiaHoglen NC et al. Liver Transpl. 2007 Mar;13(3):361-6.
DOI: 10.1002/lt.21016.

Caspase inhibition improves ischemia-reperfusion injury after lung transplantation
Quadri SM et al. Am J Transplant. 2005 Feb;5(2):292-9.
DOI: 10.1111/j.1600-6143.2004.00701.x.

Characterization of IDN-6556 (3-{2-(2-tert-Butylphenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor
Hoglen NC et al. J Pharmacol Exp Ther. 2004 May;309(2):634-40.
DOI: 10.1124/jpet.103.062034.

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse
Canbay A et al. J Pharmacol Exp Ther. 2004 Mar;308(3):1191-6.
DOI: 10.1124/jpet.103.060129.

Posters & Abstracts

Intestinal Dysbiosis Augments Liver Disease Progression Via NLRP3 in a Murine Model of Primary Sclerosing Cholangitis
Liao L et al. Abstract of oral presentation at AASLD November 2018.
Abstract 25.

Molecular mechanisms underlying the effects of emricasan in portal hypertension and chronic liver disease: the hepato-sinusoidal cross-talk matters
Gracia-Sancho J et al. Poster presented at AASLD November 2018.
Poster 1344.

The gut-liver axis is essential for disease progression in the Mdr2−/− mouse model of primary sclerosing cholangitis
Liao L et al. Abstract of oral presentation at EASL April 2018.
Abstract PS-004.

Cholestasis induced intestinal dysbiosis augments liver disease in a murine model of primary sclerosing cholangitis
Liao L et al. Abstract of poster presented at AASLD October 2017.
Abstract 287.

The pancaspase inhibitor emricasan improves the phenotype of hepatocytes from human and rat cirrhotic livers without evidence of hepatotoxicity
Ortega-Ribera M et al. Poster presented at ISCHS June 2017.
Poster PS.18.

The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression
Gracia-Sancho J et al. Poster presented at AASLD November 2016.
Poster 2097.

Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases
Eguchi A et al. Poster presented at AASLD November 2016.
Poster 2098.

The potent pan-caspase inhibitor IDN-7314 does not affect tumor growth rate nor does it antagonize the efficacy of sorafenib in models of hepatocellular carcinoma
Spada A et al. Poster presented at EASL April 2016.
Poster FRI-078.

Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation
Eguchi A et al. Poster presented at AASLD November 2015.
Abstract 1522.

Carcinogenicity Assessment of the Pan-Caspase Inhibitor, Emricasan, in Tg.rasH2 Mice
Elbekai, RH et al. Poster Presented at SOT March 2015.
Abstract 615.

Safety and efficacy of the pan-caspase inhibitor IDN-6556 on the treatment of non-alcoholic fatty liver and insulin resistance
Lu W et al. Poster Presented at EASL April 2013.
Abstract 1296 (S523): J Hepatol 2013 Apr;58:S409-S566.

Pan-Caspase Inhibition Protects Against Fibrotic NASH Induced By Choline Deficient Amino Acid Defined Diet (CDAA)
Lu W et al. Poster Presented at EASL April 2013.
Abstract 292 (S123): J Hepatol 2013 Apr;58:S63-S227.

Back to top

Mechanism of Action Resources




Back to top

Liver Disease Resources

Chronic Liver Disease



Back to top